Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 15, 2025
Context: This filing announces a significant regulatory milestone: the U.S. Food and Drug Administration (FDA) has granted accelerated approval for an additional indication for Wegovy® (semaglutide 2.4 mg). The drug is now approved for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (stages F2 to F3), in combination with a reduced calorie diet and increased physical activity.
Key Financial Metrics
This filing is a regulatory announcement regarding clinical trial results and product approval. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Clinical Data
The primary material change is the expansion of Wegovy®'s approved indications in the United States. The approval is based on Part 1 of the Phase 3 ESSENCE trial. Key clinical outcomes at week 72 compared to placebo include:
- Improvement in liver fibrosis with no worsening of steatohepatitis: 36.8% of patients treated with Wegovy® vs. 22.4% on placebo.
- Resolution of steatohepatitis with no worsening of liver fibrosis: 62.9% of patients treated with Wegovy® vs. 34.3% on placebo.
Wegovy® is now uniquely positioned as the first and only GLP-1 treatment approved for MASH. Regulatory filings for this indication have also been submitted in the EU (February 2025) and Japan (May 2025).
Guidance, Outlook, and Management Commentary
Management Commentary: Martin Holst Lange, Executive Vice President and Chief Scientific Officer, stated that MASH represents a significant health burden, affecting one in three people with overweight or obesity worldwide. In the U.S. alone, approximately 22 million people are estimated to live with MASH. Management emphasizes that the new treatment not only halts disease activity but helps reverse liver damage.
Outlook and Future Trials: Part 2 of the ESSENCE trial, which aims to demonstrate that semaglutide lowers the risk of liver-related clinical events over 240 weeks, is expected to read out in 2029.
Risks and Contingencies: The approval is designated as "accelerated," which typically implies that confirmatory trials (Part 2 of ESSENCE) are required to verify clinical benefit. The filing notes that MASH is a progressive disease that can be fatal if not managed and carries a higher risk of progression to advanced liver disease and liver cancer.
Investor Verification Checklist
- Verify the specific patient population criteria for the new MASH indication (noncirrhotic, F2-F3 fibrosis).
- Monitor the timeline and results of Part 2 of the ESSENCE trial, expected in 2029, to confirm long-term clinical event reduction.
- Track commercial launch details and pricing strategy for Wegovy® in the MASH indication in the U.S., EU, and Japan.
- Assess the potential impact of this approval on future revenue projections given the estimated 22 million U.S. patients with MASH.
- Review any potential supply chain constraints for semaglutide given the expansion of indications.